Invivyd, Inc. (NASDAQ:IVVD) Given Average Rating of “Hold” by Analysts

Invivyd, Inc. (NASDAQ:IVVD) has been given an average recommendation of “Hold” by the six research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $8.00.

A number of research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a research note on Tuesday, August 18th. Weiss Ratings cut Invivyd from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of Invivyd in a research report on Thursday. BTIG Research restated a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Finally, Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th.

Invivyd Stock Performance

Shares of Invivyd stock opened at $0.90 on Friday. Invivyd has a 52-week low of $0.53 and a 52-week high of $3.07. The company has a fifty day moving average of $0.78 and a 200-day moving average of $1.19. The stock has a market capitalization of $265.31 million, a price-to-earnings ratio of -2.73 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last issued its earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The business had revenue of $14.29 million during the quarter, compared to analysts’ expectations of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. On average, equities research analysts forecast that Invivyd will post -0.51 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Jill Andersen sold 37,256 shares of Invivyd stock in a transaction on Monday, August 17th. The shares were sold at an average price of $0.72, for a total value of $26,824.32. Following the transaction, the insider directly owned 314,480 shares of the company’s stock, valued at $226,425.60. The trade was a 10.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 228,024 shares of company stock valued at $176,540 in the last quarter. 12.25% of the stock is currently owned by company insiders.

Institutional Trading of Invivyd

A number of institutional investors have recently modified their holdings of the company. Chicago Partners Investment Group LLC bought a new stake in shares of Invivyd in the first quarter worth about $25,000. Bronte Capital Management Pty Ltd. bought a new position in shares of Invivyd during the fourth quarter valued at approximately $27,000. DRW Securities LLC purchased a new stake in Invivyd in the fourth quarter worth $27,000. ProShare Advisors LLC purchased a new stake in Invivyd in the fourth quarter worth $30,000. Finally, State of Wyoming bought a new stake in Invivyd in the fourth quarter valued at $30,000. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.